Last updated on November 2017

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Evolocumab (AMG 145) on LDL-C in Subjects With Type 2 Diabetes Mellitus and Hypercholesterolemia/Mixed Dyslipidemia Protocol Number (AMG 145/Evolocumab) 20130287


Brief description of study

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Evolocumab (AMG 145) on LDL-C in Subjects With Type 2 Diabetes Mellitus and Hypercholesterolemia/Mixed Dyslipidemia Protocol Number (AMG 145/Evolocumab) 20130287

Detailed Study Description

Receive Evolocumab or Placebo for the treatment of Diabetics with High Cholesterol.

Clinical Study Identifier: TX81978

Contact Investigators or Research Sites near you

Start Over

Martha Quinones, CRC

Clinical Research of South Florida
Coral Gables, FL USA

Martha Quinones, CRC

Clinical Research of South Florida
Coral Gables, FL USA